Roth Capital Expects Weaker Earnings for Sensus Healthcare

Sensus Healthcare, Inc. (NASDAQ:SRTS) – Research analysts at Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for shares of Sensus Healthcare in a research note issued to investors on Thursday, May 15th. Roth Capital analyst J. Wittes now expects that the company will post earnings per share of $0.03 for the quarter, down from their prior forecast of $0.08. The consensus estimate for Sensus Healthcare’s current full-year earnings is $0.32 per share. Roth Capital also issued estimates for Sensus Healthcare’s Q4 2025 earnings at $0.18 EPS, FY2026 earnings at $0.19 EPS and FY2027 earnings at $0.22 EPS.

Several other research firms have also recently weighed in on SRTS. Maxim Group dropped their price objective on shares of Sensus Healthcare from $14.00 to $10.00 and set a “buy” rating for the company in a research report on Monday. HC Wainwright restated a “buy” rating and set a $12.00 target price on shares of Sensus Healthcare in a research report on Friday, April 4th. Finally, Lake Street Capital decreased their price target on Sensus Healthcare from $18.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th.

Sensus Healthcare Trading Up 1.5%

Shares of SRTS stock opened at $4.80 on Monday. Sensus Healthcare has a 1 year low of $4.01 and a 1 year high of $9.33. The firm’s 50 day moving average is $4.62 and its 200-day moving average is $6.09. The firm has a market capitalization of $79.18 million, a price-to-earnings ratio of 12.00 and a beta of 1.30.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.16) EPS for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.20). The company had revenue of $8.34 million for the quarter, compared to the consensus estimate of $7.23 million. Sensus Healthcare had a return on equity of 12.60% and a net margin of 15.90%.

Hedge Funds Weigh In On Sensus Healthcare

Large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. bought a new stake in shares of Sensus Healthcare during the 4th quarter valued at $27,000. Barclays PLC bought a new stake in Sensus Healthcare in the fourth quarter valued at about $35,000. Larson Financial Group LLC bought a new stake in Sensus Healthcare in the first quarter valued at about $26,000. BNP Paribas Financial Markets acquired a new position in Sensus Healthcare in the fourth quarter valued at about $47,000. Finally, IFP Advisors Inc bought a new position in Sensus Healthcare during the fourth quarter worth about $95,000. 25.30% of the stock is currently owned by institutional investors and hedge funds.

Sensus Healthcare Company Profile

Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.